This study used the linked SEER-Medicare database. The interpretation and reporting of these data are the sole responsibility of the authors. The authors acknowledge the efforts of the NCI; the Office of Research, Development and Information, CMS; Information Management Services, Inc.; and the SEER Program tumor registries in the creation of the SEER-Medicare database.
Results of this study were presented in part at the 57th American Society of Hematology Annual Meeting & Exposition; December 4–8, 2015; Orlando, FL.
Dr. Olszewski has disclosed that he receives consulting fees from Bristol-Myers Squibb and institutional research support from Genentech and TG Therapeutics, and is supported by the ASH Research scholar award. Dr. Mantripragada has disclosed that he has no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors. Dr. Castillo has disclosed that he receives consulting fees from Otsuka and research funding from Millennium, Pharmacyclics, and Gilead Sciences. This research was funded by Alpert Medical School of Brown University.
See JNCCN.org for supplemental online content.
Boslooper K, Kibbelaar R, Storm H et al.. Treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone is beneficial but toxic in very elderly patients with diffuse large B-cell lymphoma: a population-based cohort study on treatment, toxicity and outcome. Leuk Lymphoma 2014;55:526–532.
- Search Google Scholar
- Export Citation
. Boslooper K Kibbelaar R Storm H Treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone is beneficial but toxic in very elderly patients with diffuse large B-cell lymphoma: a population-based cohort study on treatment, toxicity and outcome. Leuk Lymphoma 2014; 55: 526– 532.
Delarue R, Tilly H, Mounier N et al.. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. Lancet Oncol 2013;14:525–533.
Coiffier B, Lepage E, Briere J et al.. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–242.
Habermann TM, Weller EA, Morrison VA et al.. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24:3121–3127.
Pfreundschuh M, Schubert J, Ziepert M et al.. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008;9:105–116.
Hamlin PA, Satram-Hoang S, Reyes C et al.. Treatment patterns and comparative effectiveness in elderly diffuse large B-cell lymphoma patients: a surveillance, epidemiology, and end results-medicare analysis. Oncologist 2014;19:1249–1257.
Hutchins LF, Unger JM, Crowley JJ et al.. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999;341:2061–2067.
Gladman JR, Conroy SP, Ranhoff AH, Gordon AL. New horizons in the implementation and research of comprehensive geriatric assessment: knowing, doing and the ‘know-do’ gap. Age Ageing 2016;45:194–200.
Spina M, Balzarotti M, Uziel L et al.. Modulated chemotherapy according to modified comprehensive geriatric assessment in 100 consecutive elderly patients with diffuse large B-cell lymphoma. Oncologist 2012;17:838–846.
Olivieri A, Gini G, Bocci C et al.. Tailored therapy in an unselected population of 91 elderly patients with DLBCL prospectively evaluated using a simplified CGA. Oncologist 2012;17:663–672.
Extermann M, Boler I, Reich RR et al.. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer 2012;118:3377–3386.
Olszewski AJ, Winer ES, Castillo JJ. Improved survival with rituximab-based chemoimmunotherapy in older patients with extranodal diffuse large B-cell lymphoma. Leuk Res 2014;38:866–873.
Hershman DL, McBride RB, Eisenberger A et al.. Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma. J Clin Oncol 2008;26:3159–3165.
Odejide OO, Cronin AM, Davidoff AJ et al.. Limited stage diffuse large B-cell lymphoma: comparative effectiveness of treatment strategies in a large cohort of elderly patients. Leuk Lymphoma 2015;56:716–724.
Williams JN, Rai A, Lipscomb J et al.. Disease characteristics, patterns of care, and survival in very elderly patients with diffuse large B-cell lymphoma. Cancer 2015;121:1800–1808.
Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol 2000;53:1258–1267.
Olszewski AJ, Castillo JJ. Comparative outcomes of oncologic therapy in gastric extranodal marginal zone (MALT) lymphoma: analysis of the SEER-Medicare database. Ann Oncol 2013;24:1352–1359.
Davidoff AJ, Gardner LD, Zuckerman IH et al.. Validation of disability status, a claims-based measure of functional status for cancer treatment and outcomes studies. Med Care 2014;52:500–510.
Davidoff AJ, Zuckerman IH, Pandya N et al.. A novel approach to improve health status measurement in observational claims-based studies of cancer treatment and outcomes. J Geriatr Oncol 2013;4:157–165.
Centers for Medicare & Medicaid Services. Berenson-Eggers Type of Service (BETOS). Available at: https://www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/BETOS.html. Accessed January 20, 2016.
Smith TJ, Bohlke K, Lyman GH et al.. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2015;33:3199–3212.
White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Stat Med 2011;30:377–399.
Royston P, Lambert PC. Flexible Parametric Survival Analysis Using Stata: Beyond the Cox Model. College Station, TX: Stata Press; 2011.
Ziepert M, Hasenclever D, Kuhnt E et al.. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol 2010;28:2373–2380.
Zhou Z, Sehn LH, Rademaker AW et al.. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood 2014;123:837–842.
Feugier P, Van Hoof A, Sebban C et al.. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005;23:4117–4126.
Morrison VA, Hamlin P, Soubeyran P et al.. Approach to therapy of diffuse large B-cell lymphoma in the elderly: the International Society of Geriatric Oncology (SIOG) expert position commentary. Ann Oncol 2015;26:1058–1068.
Terschuren C, Gierer S, Brillant C et al.. Are patients with Hodgkin lymphoma and high-grade non-Hodgkin lymphoma in clinical therapy optimization protocols representative of these groups of patients in Germany? Ann Oncol 2010;21:2045–2051.
van der Poel MW, Mulder WJ, Ossenkoppele GJ et al.. Factors that influence treatment decision-making in elderly DLBCL patients: a case vignette study. Ann Hematol 2015;94:1373–1379.
Thieblemont C, Grossoeuvre A, Houot R et al.. Non-Hodgkin's lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome. Ann Oncol 2008;19:774–779.
Soubeyran P, Fonck M, Blanc-Bisson C et al.. Predictors of early death risk in older patients treated with first-line chemotherapy for cancer. J Clin Oncol 2012;30:1829–1834.
Hurria A, Togawa K, Mohile SG et al.. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 2011;29:3457–3465.
Mareschal S, Lanic H, Ruminy P et al.. The proportion of activated B-cell like subtype among de novo diffuse large B-cell lymphoma increases with age. Haematologica 2011;96:1888–1890.
Pfreundschuh M, Trumper L, Kloess M et al.. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004;104:634–641.
Peyrade F, Jardin F, Thieblemont C et al.. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol 2011;12:460–468.
Walter E, Schmitt T, Dietrich S et al.. Rituximab and bendamustine in patients with CD20+ diffuse large B-cell lymphoma not eligible for cyclophosphamide, doxorubicin, vincristine and prednisone-like chemotherapy. Leuk Lymphoma 2012;53:2290–2292.